CagriSema FAQ: common questions answered
An unapproved cagrilintide–semaglutide combination with phase 3 weight-loss and diabetes results.
Also called: Cagrilintide/semaglutide, Cagrilintide-semaglutide, CagriSema 2.4 mg/2.4 mg.
Amylin analogues · Combination of an amylin analogue and a GLP-1 receptor agonist.
- Is CagriSema FDA-approved? No. CagriSema application filed December 2025; no approved combination label found.
- How do people take it? Under the skin, once weekly. 68 weeks. Source: studied in a trial.
- What's the difference between CagriSema and Tirzepatide? CagriSema: an unapproved cagrilintide–semaglutide combination with phase 3 weight-loss and diabetes results. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: occasional reports add a blend to an existing weight-loss drug.
- Can I take it with Tirzepatide? Occasional reports add a blend to an existing weight-loss drug. Adds GLP-1 exposure to semaglutide already in the blend; no verified human triple-stack evidence. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Application of the S0 rule to unapproved cagrilintide; not an individual named listing. Confirm with the athlete’s anti-doping body.
- How long does a mixed vial last? No validated stability period for home blends was found; a clear solution does not prove sterility.
Related to CagriSema
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
- Pramlintide: A diabetes medicine that copies a hormone released with insulin; Symlin products are discontinued.
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society., Mozaffarian D et al. · The American journal of clinical nutrition · 2025
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
- Chest pain, NHS
- European Medicines Agency decision P/0307/2023 of 4 August 2023 on the granting of a product specific waiver for cagrilintide / semaglutide (EMEA-003059-PIP02-23)
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, US Food and Drug Administration
- PIP Search Page, MHRA
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products
- Vision loss, NHS
- Wegovy PI, Novo Nordisk
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study., Rosenstock J et al. · Lancet (London, England) · 2026
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study., Buse JB et al. · The lancet. Diabetes & endocrinology · 2026
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1., Verma S et al. · Hypertension (Dallas, Tex. : 1979) · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.